Skip to content
As Medicare open enrollment nears, seniors will face difficult choices despite CMS’ rosy assessment
Prescription drug coverage in Medicare will see sweeping changes – for both health plans and for the millions of American seniors they serve – […]
As Medicare open enrollment nears, ‘M3P’ and the out-of-pocket cap loom large
Medicare beneficiaries will soon need to begin thinking about their coverage for 2025, with the open enrollment period opening on Oct. 15. The next
As Medicare open enrollment nears, ‘M3P’ and the out-of-pocket cap loom large Read More »
CMS listens to BIO and understands proposed policies could have harmed patients, innovation
A new suite of rules governing drug rebates in Medicaid has been finalized, removing months of uncertainty about whether the Centers for Medicare and
BIO’s view: Sanders’ latest attack on innovation misses realities about groundbreaking drugs
Yesterday, Sen. Bernie Sanders held a meeting about the new class of groundbreaking diabetes and weight-loss medicines. Next week, he will hold a hearing
Four key facts ahead of tomorrow’s drug pricing hearing
The Senate Finance Committee will hold a hearing tomorrow on “understanding the benefits of the Inflation Reduction Act.” Expect to hear a lot of rhetoric
Four key facts ahead of tomorrow’s drug pricing hearing Read More »
New survey checks pulse on voters’ concerns for innovation and biomanufacturing
Voters want to bolster American manufacturing across biopharmaceutical and biotechnology sectors, according to a new public opinion survey conducted by Morning Consult for the
New survey checks pulse on voters’ concerns for innovation and biomanufacturing Read More »
The economics of the Inflation Reduction Act’s impact on innovation
The announcement of “maximum fair prices” for the first 10 medicines targeted under the Inflation Reduction Act (IRA) has renewed questions and concerns about
The economics of the Inflation Reduction Act’s impact on innovation Read More »
Understanding the IRA’s real-world impacts starts with understanding the innovation ecosystem
The Inflation Reduction Act (IRA) has already begun to shift the way that innovative companies are investing in future breakthroughs. Over the past few
FTC to air grievances with PBMs’ abusive practices
The Federal Trade Commission will host an open meeting this morning, and fortunately, drug middlemen are on the agenda. The meeting will review the findings
FTC to air grievances with PBMs’ abusive practices Read More »
CMS overreach will impede innovation
In implementing the Inflation Reduction Act (IRA), the Centers for Medicare and Medicaid Services (CMS) has made efforts to unnecessarily broaden the law with
CMS overreach will impede innovation Read More »